An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
University of Cambridge · Foundation for Liver Research · +82 more institutions
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD 'human proximity score' to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that…
Citation impact
- FWCI
- 75.94
- Percentile
- 100%
- References
- 60
Authors
238- MVMichèle VaccaCorresponding
University of Cambridge, Foundation for Liver Research, Wellcome/MRC Institute of Metabolic Science, University of Bari Aldo Moro
- IKIoannis Kamzolas
European Bioinformatics Institute, University of Cambridge, Wellcome/MRC Institute of Metabolic Science
- LMLea Mørch Harder
Novo Nordisk (Denmark)
- FOFiona Oakley
Newcastle University
- CTChristian Trautwein
RWTH Aachen University
Topics & keywords
- Steatohepatitis
- Fatty liver
- Steatosis
- Cirrhosis
- Fibrosis
- Liver disease
- Disease
- Medicine
- No poverty
Funding
- PPfizer
- AAstraZeneca
- SSanofi
- “C“la Caixa” FoundationAward: LCF/PR/HR21/52410028
- IBIntegrated BioBank of Luxembourg
- FFFoundation for Liver Research
- EBEuropean Bioinformatics Institute
- UDUniversità degli Studi di MilanoAward: Horizon 2020
- EMEuropean Molecular Biology Laboratory
- EFEuropean Federation of Pharmaceutical Industries and AssociationsAward: 777377
- NINational Institute for Health and Care ResearchAward: MC_UU_00014/5
- BHBritish Heart Foundation
- NUNewcastle University
- ECEuropean CommissionAwards: PE00000003, 777377, CN00000041, CN00000013
- MDMinistero dell’Istruzione, dell’Università e della RicercaAwards: P202222FCC, CN00000013, CN00000041, PE00000003
- NNNovo Nordisk
- AIAssociazione Italiana per la Ricerca sul CancroAward: IG27521
- UDUniversita degli Studi di Bari Aldo MoroAward: S06-miRNASH
- GUGöteborgs Universitet
- RARWTH Aachen University
- FMFakultet Medicinskih Nauka, Univerziteta U Kragujevcu
- IMInnovative Medicines InitiativeAward: 777377
- FEFundación Española para la Ciencia y la TecnologíaAward: PTDC/MED-FAR/3492/2021
- NINational Institutes of HealthAwards: 5P30CA196521, R01 DK128289, NIH R01
- NPNovartis Pharma
- NINovartis Institutes for BioMedical Research
- HEHORIZON EUROPE Framework Programme
- SDSanofi-Aventis Deutschland
- MRMedical Research CouncilAwards: MC_UU_00014/2, MR/R023026/1, 1948243, MR/K0019494/1, MC_UU_00014/5, MC_UU_00014/5, MR/R023026/1, MR/K001949/1, MC_UP_2201/1, 1948243
- SASahlgrenska Akademin
- FOFaculty of Medical Sciences, Newcastle University
- NNNIHR Newcastle Biomedical Research CentreAward: 777377
- NCNational Cancer InstituteAward: NCI 5P30CA196521
- NCNIH Clinical CenterAwards: NCI 5P30CA196521-08, NIH R01 DK128289, NIH R01 DK136016